Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

228.79 +3.77 (+1.68%)
Streaming Delayed Price Updated: 1:09 PM EDT, Jul 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
38 39 Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Kiora Pharmaceuticals (NASDAQ:KPRX 
Via Benzinga
44 Stocks Moving In Thursday's Mid-Day Session
Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) jumped 52.3% to $1.3396. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors. Future... 
Via Benzinga
What Are Whales Doing With Biogen
A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 11 strange trades. If we... 
Via Benzinga
Biogen Stock Flies As Report Suggests Samsung Group Could Buy It
Biogen reportedly approached Samsung Group to negotiate a buyout. 
Via Investor's Business Daily
Expert Ratings For Biogen
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following an... 
Via Benzinga
Analyst Ratings For Biogen
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) withi... 
Via Benzinga
Biogen Stock Dives As Samsung Reportedly Denies Rumored $42 Billion Buyout
Biogen is under pressure amid troubles for its Alzheimer's and multiple sclerosis meds. 
Via Investor's Business Daily
Why Biogen Shares Are Falling Today
Biogen Inc (NASDAQ: BIIB) is trading lower Thursday morning after Samsung BioLogics denied that its parent company, Samsung Group, is looking to buy Biogen. Korea Economic Daily... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Kiora Pharmaceuticals (NASDAQ:KPRX) stock moved upwards by 20.4% to $1.06 during Thursday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
The U.S Indices Continue To Break Price Records Despite Year-End Economic Slowdown
The US oil inventories dropped nearly 3.6 million barrels. In the background of such data, given the reduction of concerns about the impact of Omicron on demand for petroleum products, the energy... 
Via Talk Markets
20 Stocks Moving in Thursday's Pre-Market Session
Gainers BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) rose 33.6% to $3.10 in pre-market trading. BiondVax reported successful closing of $9.8 million follow-on underwritten... 
Via Benzinga
5 Stocks To Watch For Thursday, Dec. 30
Five stocks that you should keep in mind today. (Thursday, Dec. 30) 
Via Talk Markets
5 Stocks To Watch For December 30, 2021
Some of the stocks that may grab investor focus today are: Four Corners Property Trust, Inc. (NYSE: FCPT) reported acquisition of three Mr. Tire Properties for $2.5 million. The... 
Via Benzinga
Peering Into Biogen Inc's Recent Short Interest
Biogen Inc's (NASDAQ:BIIB) short percent of float has risen 16.43% since last its last report. The company recently reported that it has 2.39 million shares sold short, which is 1... 
Via Benzinga
Annovis Bio on Its Positive Results in Alzheimer's and Parkinson's Clinical Trials
Image provided by Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022
Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout... 
Via Benzinga
Here's How Much $100 Invested In Biogen 15 Years Ago Would Be Worth Today
Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.22% on an annualized basis. Buying $100 In BIIB: 15 years ago, an investor could have purchased 2.20... 
Via Benzinga
Christmas is Coming
November saw a very modest increase in consumer spending, 0.6%. That means we are probably making up for it this month. 
Via Talk Markets
BAD ETF: The Top “Sin Stock” Holdings in the New Anti-ESG Fund That Debuts Today
There's a new ETF on the block from BAD Investment Company and it seeks to offer investments in sin stocks for interested traders. 
Via InvestorPlace
10 Biggest Price Target Changes For Wednesday
Barclays lifted the price target on FactSet Research Systems Inc. (NYSE: 
Via Benzinga
Biogen Slashes Alzheimer's Treatment Price Amid Launch 'Gone Awry'
A maintenance dose of the Alzheimer's drug will cost $28,200 per year. 
Via Investor's Business Daily
After Much Criticism, Biogen Slashes Aduhelm Price In Half
In a surprise move, Biogen Inc (NASDAQ: BIIB) announced that it would slash the price of its controversial Alzheimer's drug Aduhelm in half from $56,000 to... 
Via Benzinga
10 Biggest Price Target Changes For Monday
JP Morgan raised the price target on Public Storage (NYSE: 
Via Benzinga
EMA's Committee Gives Thumbs Down To Biogen's Controversial Alzheimer's Drug, As Expected
The European Medicines Agency has recommended the European Commission to reject Biogen Inc's (NASDAQ: BIIB) Aduhelm, an expected blow to its hopes of finding a... 
Via Benzinga
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral... 
Via Benzinga
Biogen Outlines Aduhelm's Confirmatory Trial Plans, Data Expected In 2026
Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) are looking to get initial data from the FDA-mandated confirmatory trial for its Alzheimer’s... 
Via Benzinga
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug... 
Via Benzinga
Eli Lilly Pops On Boosted 2021 Outlook As Covid Brings In $2.1 Billion
The U.S. government recently signed a deal for Lilly's Covid antibodies. 
Via Investor's Business Daily
More Specificity is What the Doctor Ordered
Photo by Steven HWG on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner... 
Via Benzinga
Amid Shaky Launch Of Aduhelm, Biogen Mulls Substantial Layoffs: STAT News Report
Between slow sales, safety concerns, and possible European rejection for Alzheimer's disease drug Aduhelm, Biogen Inc (NASDAQ: BIIB) is planning large-scale layoffs... 
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
38 39 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.